Scarica l'app Stockscreener
23.83
2.94%
0.68
Dopo l'orario di chiusura:
23.60
-0.23
-0.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is Sarepta Therapeutics Inc. stock resilient to inflationQuarterly Profit Summary & Daily Technical Stock Forecast Reports - ulpravda.ru
Can Sarepta Therapeutics Inc. (AB3A) stock ride next bull market cycleBear Alert & Safe Entry Momentum Stock Tips - ulpravda.ru
Why (SRPT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Sarepta Therapeutics seeks clinical trial clearance for SRP-1005 - BioWorld MedTech
Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com
Leerink Partners maintains Market Perform rating on Sarepta stock ahead of 2026 data - Investing.com UK
Assessing Sarepta Therapeutics (SRPT) Valuation After SRP-1005 Huntington’s Disease Trial Application - Yahoo Finance
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigat - pharmiweb.com
Sarepta submits clinical trial application for Huntington’s disease drug By Investing.com - Investing.com India
Sarepta submits clinical trial application for Huntington’s disease drug - Investing.com
Sarepta (SRPT) Moves Forward with New Clinical Trial Application for Huntington's Treatment - GuruFocus
Sarepta submits clinical trial application for Huntington's disease drug - StreetInsider
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease - Yahoo Finance
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2026 world cup usa national team round of 32 star players high defensive line expert forecast preview - Улправда
Standing by Our Decision: How EXONDYS 51 Became Part of Our Treatment Plan - Muscular Dystrophy News
Buybacks Report: What risks investors should watch in Sarepta Therapeutics Inc stockBreakout Watch & Intraday High Probability Setup Alerts - moha.gov.vn
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - New Castle News
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Biotech Pioneer with a Mixed Valuation Outlook - DirectorsTalk Interviews
Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC - MarketBeat
United States Neuromuscular Disease Therapeutics Market - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny - MSN
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 - openPR.com
Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours - MSN
Sarepta Therapeutics Earnings Notes - Trefis
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Here's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Sarepta to refinance $291M of existing notes due 2027 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire
Aug Intraday: Will Sarepta Therapeutics Inc stock split attract more investorsOil Prices & Verified Momentum Stock Watchlist - moha.gov.vn
Have Insiders Sold Sarepta Therapeutics Shares Recently? - simplywall.st
How Sarepta Therapeutics Inc. stock compares to industry benchmarksPortfolio Gains Report & Real-Time Market Trend Scan - ulpravda.ru
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Extends Debt Maturities with New Notes - TipRanks
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities - Investing.com
Sarepta Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets
What Does the Market Think About Sarepta Therapeutics Inc? - Benzinga
Is Sarepta Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Patterns & Reliable Price Action Trade Plans - DonanımHaber
Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares - MarketBeat
Insider Sale: Chief Operating Officer of $SRPT Sells 13,187 Shares - Quiver Quantitative
Sarepta Therapeutics COO Sells Shares - TradingView — Track All Markets
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - ACCESS Newswire
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Finviz
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance
Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' (SRPT) Risk‑Reward Narrative? - Sahm
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):